191 related articles for article (PubMed ID: 1838869)
21. [Classification, staging and prognostic indices for multiple myeloma].
Hotta T
Nihon Rinsho; 2007 Dec; 65(12):2161-6. PubMed ID: 18069256
[TBL] [Abstract][Full Text] [Related]
22. New prognostic factors in multiple myeloma.
Bettini R; Rapazzini P; Marrapodi E
Haematologica; 1987; 72(1):102-3. PubMed ID: 3108088
[No Abstract] [Full Text] [Related]
23. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
[TBL] [Abstract][Full Text] [Related]
24. Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma.
Rossi D; Fangazio M; De Paoli L; Puma A; Riccomagno P; Pinto V; Zigrossi P; Ramponi A; Monga G; Gaidano G
Cancer; 2010 May; 116(9):2188-200. PubMed ID: 20198709
[TBL] [Abstract][Full Text] [Related]
25. [The prognosis of patients with multiple myeloma--the aspect of histological distribution to the renal tissue and serum level of beta 2-MG].
Inoue Y; Suzuki K; Enomoto H; Takemura T; Nakamura K
Rinsho Ketsueki; 1992 Aug; 33(8):1012-6. PubMed ID: 1404855
[TBL] [Abstract][Full Text] [Related]
26. [Prognositic factors in multiple myeloma].
Nagura E
Nihon Rinsho; 2007 Dec; 65(12):2351-6. PubMed ID: 18069282
[TBL] [Abstract][Full Text] [Related]
27. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
[TBL] [Abstract][Full Text] [Related]
28. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
[TBL] [Abstract][Full Text] [Related]
29. Additional predictive value of serum unsaturated vitamin B12 proteins in multiple myeloma.
Arnalich F; Zamorano AF; Martinez-Hernández P; Pena JM; Barbado FJ; Vázquez JJ
J Med; 1990; 21(5):277-86. PubMed ID: 2079617
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of stratification systems in multiple myeloma. I. Risk categories (good and poor risk).
Scudla V; Indrák K
Neoplasma; 1985; 32(4):469-79. PubMed ID: 4047258
[TBL] [Abstract][Full Text] [Related]
31. [Prognostic effect of beta 2-microglobulin in multiple myeloma].
Ortega F; González M; Moro MJ; Gascón A; Duarte I; Martín M; Hernández J; Jiménez-Galindo R; Portero JA; Sanz M
Med Clin (Barc); 1992 Nov; 99(17):645-8. PubMed ID: 1447935
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in multiple myeloma.
Kyle RA
Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase.
Diem H; Fateh-Moghadam A; Lamerz R
Clin Investig; 1993 Nov; 71(11):918-23. PubMed ID: 8312685
[TBL] [Abstract][Full Text] [Related]
34. Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma.
Bataille R; Grenier J; Sany J
Anticancer Res; 1987; 7(3 Pt B):513-5. PubMed ID: 3307602
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.
Durie BG; Stock-Novack D; Salmon SE; Finley P; Beckord J; Crowley J; Coltman CA
Blood; 1990 Feb; 75(4):823-30. PubMed ID: 2405920
[TBL] [Abstract][Full Text] [Related]
36. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
37. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
38. [Beta 2 microglobulin in some hematologic neoplasms].
Rodríguez MA; Lira P; Foradori A; Grebe G
Rev Med Chil; 1989 Jun; 116(6):538-42. PubMed ID: 2664940
[TBL] [Abstract][Full Text] [Related]
39. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
40. [Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].
Franco M; Fuzibet JG; Cassuto JP; Pesce A; Ziegler G; Dujardin P
Rev Rhum Mal Osteoartic; 1985 Nov; 52(11):619-23. PubMed ID: 3909365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
